Search

Your search keyword '"Ritter, Gerd"' showing total 683 results

Search Constraints

Start Over You searched for: Author "Ritter, Gerd" Remove constraint Author: "Ritter, Gerd"
683 results on '"Ritter, Gerd"'

Search Results

2. Defining the Critical Hurdles in Cancer Immunotherapy

5. Recombinant NY-ESO-1 Protein with ISCOMATRIX Adjuvant Induces Broad Integrated Antibody and CD4+ and CD8+ T Cell Responses in Humans

18. Data from Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer

20. Supplementary Table 2 from Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer

21. Supplementary Figure Legends from Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer

22. Supplementary Figure 2 from Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer

23. Supplementary Figure 1 from Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer

24. Supplementary Table 1 from Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer

26. Supplementary Figure 1 from Phase I Clinical Trial of Mixed Bacterial Vaccine (Coley's Toxins) in Patients with NY-ESO-1 Expressing Cancers: Immunological Effects and Clinical Activity

27. Supplementary Figure 5 from Prostate Cancer Progression Correlates with Increased Humoral Immune Response to a Human Endogenous Retrovirus GAG Protein

28. Supplementary Table 2 from Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients

29. Supplementary Figure 4 from Phase I Clinical Trial of Mixed Bacterial Vaccine (Coley's Toxins) in Patients with NY-ESO-1 Expressing Cancers: Immunological Effects and Clinical Activity

30. Supplementary Figure Legends from Prostate Cancer Progression Correlates with Increased Humoral Immune Response to a Human Endogenous Retrovirus GAG Protein

32. Supplementary Figure 4 from Prostate Cancer Progression Correlates with Increased Humoral Immune Response to a Human Endogenous Retrovirus GAG Protein

35. Supplementary Figure 2 from Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients

36. Supplementary Figure Legend from Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients

37. Supplementary Figure 3 from Prostate Cancer Progression Correlates with Increased Humoral Immune Response to a Human Endogenous Retrovirus GAG Protein

38. Supplementary Figure 2 from Prostate Cancer Progression Correlates with Increased Humoral Immune Response to a Human Endogenous Retrovirus GAG Protein

40. Supplementary Table 1 from Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients

41. Supplementary Methods and Figure Legend from Phase I Clinical Trial of Mixed Bacterial Vaccine (Coley's Toxins) in Patients with NY-ESO-1 Expressing Cancers: Immunological Effects and Clinical Activity

42. Supplementary Figure 1 from Prostate Cancer Progression Correlates with Increased Humoral Immune Response to a Human Endogenous Retrovirus GAG Protein

45. Supplementary Figure 3 from Phase I Clinical Trial of Mixed Bacterial Vaccine (Coley's Toxins) in Patients with NY-ESO-1 Expressing Cancers: Immunological Effects and Clinical Activity

46. Supplementary Figure 2 from Phase I Clinical Trial of Mixed Bacterial Vaccine (Coley's Toxins) in Patients with NY-ESO-1 Expressing Cancers: Immunological Effects and Clinical Activity

47. Supplementary Figure 3 from Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients

48. Supplementary Figure 1 from Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients

50. Supplementary Figures 1-3 from Intracellular Tumor-Associated Antigens Represent Effective Targets for Passive Immunotherapy

Catalog

Books, media, physical & digital resources